""It's unusual to me that ibogaine has been called out specifically, given that it's probably the furthest behind in the process compared to psilocybin and MDMA, which are much closer to approval," says Alan Davis, a clinical psychologist at the Ohio State University in Columbus."
"The order is "going to make things easier to advance psychedelic therapies because it lowers barriers that have been slowing progress," says Rachel Yehuda, a psychiatry specialist at the Icahn School of Medicine at Mount Sinai in New York City."
On April 18, Trump signed an executive order to facilitate research on ibogaine and other psychedelics, aiming to improve access for patients with specific illnesses. Researchers welcome this move, recognizing the potential of these substances in treating addiction, depression, and PTSD. While preliminary studies show promise for ibogaine, concerns about side effects and health service impacts remain. The order is expected to lower barriers to psychedelic therapies, advancing the research process for these controlled substances classified as Schedule I.
Read at Nature
Unable to calculate read time
Collection
[
|
...
]